Effect of spironolactone on impaired fibrinolysis of hypertensive patients

Kidney and Blood Pressure Research

Volumn 25, Issue 4, 2002, Pages 260-264

  Yalcin, Ahmet Ugur ^a,b   Dincer, Murat ^a   Aslan, Vahap ^a   Gulbas, Zafer ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Aldosterone; Fibrinolysis; Hypertension; Plasminogen activator inhibitor 1; Renin angiotensin aldosterone system; Spironolactone; Tissue plasminogen activator

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; MALE; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TREATMENT OUTCOME; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037813769     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066348     Document Type: Article

References (23)

1. Dawber TR: The Framingham study. Epidemiology of Atherosclerotic Disease. Cambridge, Harvard University Press, 1980.
2. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I: Association of blood pressure with fibrinolytic potential in the Framingham Offspring Population. Circulation 2000;25:264-269.
3. Nordt TK, Peter K, Ruef J, Kubler W, Bode C: Plasminogen activator inhibitor type-1 and its role in cardiovascular disease. Thromb Haemost 1999;82(suppl 1):14-18.
4. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA: Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: Direct link between endothelial dysfunction and atherothrombosis. Circulation 2001;103:1936-1941.
5. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor-1 in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1999;227:273-278.
6. Alexander CM, Werb Z: Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989;1:974-982.
7. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998-7002.
8. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE: Effect of activation and inhibition of renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-971.
9. Ridker PM, Gabaury CL, Conlin PR: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-1973.
10. Erdem Y, Usalan C, Haznedaroglu IC, Altun B, et al: Effect of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;12:1071-1076.
11. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A: Modulation of plasminogen activator type-1 in vivo: A new mechanism for antifibrotic effect of renin-angiotensin inhibition. Kidney Int 1997;51:164-172.
12. Nakamura C, Nakamura I, Lijun M, Vaughan DE, Fogo AB: Plasminogen activator inhibitor-1 expression is regulated by angiotensin type 1 receptor in vivo. Kidney Int 2000;58:251-259.
13. Biron P, Koiw E, Nowaczynski W: The effect of intravenous infusions of valine 5 angiotensin II and other pressor agents on urinary electrolytes and corticoids including aldosterone. J Clin Invest 1961;60:338-342.
14. Kaplan NM: Clinical Hypertension, ed 7. Baltimore, Williams & Wilkins, 1998.
15. Brilla CG, Weber KT: Mineralocorticoid excesses, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.
16. Brilla CG, Matsubara LS, Weber KT: Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-575.
17. Benetos A, Lacolley P, Safar ME: Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Atheroscler Thromb Vasc Biol 1997;17:1152-1156.
18. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-1068.
19. Brown NJ, Nakamura L, Nakamura I, Donnert E, et al: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-1227.
20. Gleerup G, Winther K: Decreased fibrinolytic activity and increased platelet function in hypertension: Possible influence of calcium antagonist. Am J Hypertens 1991;4:168S-171S.
21. Sawathiparnish P, Kumar S, Vaughan DE, Brown NJ: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002;87:448-452.
22. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 1999;341:709-717.
23. Okuba S, Mimura F, Nishmura H, et al: Angiotensin independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99:855-860.